ArticleAmerican journal of respiratory and critical care medicine2005
Using protein microarray as a diagnostic assay for non-small cell lung cancer.
Article in American journal of respiratory and critical care medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Screening for lung cancer.The Cochrane database of systematic reviews · 2013Pooled it
- High-Throughput Peptide Array Clinical Validation for Lung Adenocarcinoma Detection.ACS omega · 2025Article
- Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.Journal of experimental & clinical cancer research : CR · 2024Review
- FLU-LISA (fluorescence-linked immunosorbent assay): high-throughput antibody profiling using antigen microarrays.Immunology and cell biology · 2023Article
- Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early Diagnosis of Lung Cancer.Molecular & cellular proteomics : MCP · 2020Article
- Protein Array-based Approaches for Biomarker Discovery in Cancer.Genomics, proteomics & bioinformatics · 2017Review
- Lung cancer screening: history, current perspectives, and future directions.Archives of medical science : AMS · 2015Article
- Glycoarrays with engineered phages displaying structurally diverse oligosaccharides enable high-throughput detection of glycan-protein interactions.Biotechnology journal · 2015Article
- Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts.PloS one · 2014Article
- Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer.OncoTargets and therapy · 2013Article
- Article
- The state of molecular biomarkers for the early detection of lung cancer.Cancer prevention research (Philadelphia, Pa.) · 2012Review
- Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.Omics : a journal of integrative biology · 2011Review
- Immunogenicity of autoantigens.BMC genomics · 2011Article
- Advances in proteomic strategies toward the early detection of lung cancer.Proceedings of the American Thoracic Society · 2011Review
- Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays.Molecular & cellular proteomics : MCP · 2011Article
- Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.PloS one · 2010Article
- [Autoantibodies as the early diagnostic biomarkers for lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Review
- Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer.Cancer biology & therapy · 2010Article
- Use of a single-chain antibody library for ovarian cancer biomarker discovery.Molecular & cellular proteomics : MCP · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
rationalePhenotypic and genotypic heterogeneity of lung cancer likely precludes the identification of a single predictive marker and suggests the importance of identifying and measuring multiple markers.
objectivesWe describe the use of a fluorescent protein microarray to identify and measure multiple non-small cell lung cancer-associated antibodies and show how simultaneous measurements can be combined into a single diagnostic assay.
methodsT7 phage cDNA libraries of non-small cell lung cancer were first biopanned with plasma samples from normal subjects and patients with non-small cell lung cancer to enrich the component of tumor-associated proteins, and then applied to microarray slides. Two hundred twelve immunogenic phage-expressed proteins were identified from roughly 4,000 clones, using high-throughput screening with patient plasmas and assayed with 40 cancer and 41 normal plasma samples. Twenty patient and 21 normal plasma samples were randomly chosen and used for statistical determination of the predictive value of each putative marker. Statistical analysis identified antibody reactivity to seven unique phage-expressed proteins that were significantly different (p < 0.01) between patient and normal groups. The remaining 20 patient and 20 normal plasma samples were used as an independent test of the predictive ability of the selected markers. MAIN
resultsMeasurements of the 5 most predictive phage proteins were combined in a logistic regression model that achieved 90% sensitivity and 95% specificity in prediction of patient samples, whereas leave-one-out statistical analysis achieved 88.9% diagnostic accuracy among all 81 samples.
conclusionOur data indicate that antibody profiling is a promising approach that could achieve high diagnostic accuracy for non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.